Device used to close small hole in heart may protect against recurrent stroke
A device used to close a small hole in the heart may benefit certain stroke patients by providing an extra layer of protection for those facing years of ongoing stroke risk, according to the results of a large clinical trial led by UCLA researchers.“It is a major new treatment option for some people,” said Dr. Jeffrey Saver, director of theUCLA Comprehensive Stroke Center and lead author of the study. However, he added, “Using the device is going to have to be a considered clinical decision between the doctor and the patient about who’s the right person to get it.”Thefindings appear in the Sept. 14 New England Journal of Medicine.Over eight years, the RESPECT study (Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment) enrolled 980 people, ages 18 to 60, at 69study locations in the United States and Canada. All of the participants had experienced a stroke, possibly caused by a condition known as patent foramen ovale, known as a PFO, which is a hole in the heart that did not close the way it should after birth. Nearly half of the people in the study had suffered a major stroke.About 25 to 30 percent of people in the United States have a PFO, which typically causes no health problems and does not require treatment. However, this type of hole in the heart is the possible cause in about 10 percent of the 795,000 strokes that occur in the United States each year. Most strokes are caused by high blood pressure, narro...
Publication date: Available online 2 June 2020Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Xin Liu, Lin Shi, Xiaoshuang Dai, Huangtao Chen, Chenglin Zhang, Pei Wang, Qian Wu, Lingxia Zeng, Hong Yan
On the heels of studies showing hydroxychloroquine doesn't help patients in the hospital with Covid-19, a new study -- the first of its kind -- shows the drug doesn't work to prevent infection with the virus, either.
The United States should have 100 million doses of one candidate coronavirus vaccine by the end of the year, Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and a member of the White House Coronavirus Task Force, said Tuesday.
The Trump administration chose 5 companies as the most likely to produce a vaccine. The tally of new cases is rising in the U.S., partly because of expanded testing. Italy ends travel restrictions.
Researchers say that a malaria drug President Donald Trump took to try to prevent COVID-19 proved ineffective for that in the first large, high-quality study to test it in health workers and others closely exposed to people with the disease
The first carefully controlled trial of hydroxychloroquine given to people exposed to the coronavirus did not show any benefit.
U.S. President Donald Trump had no side effects from a two-week course of hydroxychloroquine, an anti-malaria drug that can cause heart problems, after using it as a preventive measure against the coronavirus, his White House physician said on Wednesday.
The Trump administration has selected five companies, including Moderna Inc, AstraZeneca Plc and Pfizer Inc, as the most likely candidates to produce a vaccine for the novel coronavirus, the New York Times reported on Wednesday, citing senior officials.